Compare OABI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OABI | BNR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | China |
| Employees | 114 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | OABI | BNR |
|---|---|---|
| Price | $1.86 | $23.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.67 | N/A |
| AVG Volume (30 Days) | ★ 279.2K | 13.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.84 | $136.32 |
| Revenue Next Year | $40.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $2.18 |
| 52 Week High | $3.33 | $41.72 |
| Indicator | OABI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 41.16 |
| Support Level | $1.68 | $19.72 |
| Resistance Level | $1.89 | $24.23 |
| Average True Range (ATR) | 0.11 | 1.74 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 46.15 | 31.10 |
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.